Health Care • Biotechnology: Pharmaceutical Preparations
$540.00 ▲ +10.31
(+1.95%)
MKT CAP: $136.87B • VOL: 1.54M
52W L $403 52W H $564
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$454
MEDIAN
$605
MEAN
$616
HIGH
$734
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VRTX TAPE
VRTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $653.40 | $621.00 | 2025-02-14 | $491.40 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $680.40 | $637.20 | 2025-02-06 | $507.60 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $615.60 | $594.00 | 2025-01-29 | $518.40 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $550.80 | — | 2025-01-17 | $529.20 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $475.20 | $513.00 | 2025-01-09 | $480.60 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $642.60 | $561.60 | 2024-12-18 | $469.80 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $523.80 | $545.40 | 2024-12-04 | $502.20 | -4.3% | 48% | C |